δείτε την πρωτότυπη σελίδα τεκμηρίου στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*
Alteplase for Hemodialysis access graft thrombolysis
Sofocleous, CT
Hinrichs, CR
Weiss, SH
Contractor, D and
Barone, A
Bahramipour, P
Brountzos, E
Kelekis, D
PURPOSE: To evaluate the efficacy and safety of alteplase, a recombinant
tissue plasminogen activator, in hemodialysis access graft thrombolysis.
MATERIALS AND METHODS: From November 1999 to May 2001, 68 episodes of
occlusion in 50 grafts (in 49 patients) were included in the study.
Occlusion was treated with pulse-spray (n = 41) or lyse-and-wait (n =
27) thrombolysis with use of alteplase. Balloon angioplasty of all
identified stenoses was performed. The arterial plug was mobilized with
the Fogarty maneuver.
RESULTS: Procedural success was achieved in 64 of 68 episodes (94%)
with a dose of 2-10 mg (mean = 4.13 mg) of alteplase, allowing
successful hemodialysis within 24 hours. Failures (6%) were the result
of PTA perforation (one of 68), nonnegotiable outflow occlusion (one of
68), delayed bleeding (one of 68), and balloon bursting and shearing
becoming occlusive within the graft (one of 68). Primary and secondary
patency rates were 72% and 87% at 30 days, 57% and 80% at 90 days,
and 44% and 72% at 180 days, respectively. Arterial emboli (two of 68)
were treated by Fogarty balloon retrieval and alteplase infusion locally
over the course of 20 minutes. One of two PTA perforations was
controlled by balloon tamponade.
CONCLUSION: Alteplase can be used successfully for hemodialysis graft
thrombolysis.
(EN)
*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.
Alteplase for Hemodialysis access graft thrombolysis
Alteplase for Hemodialysis access graft thrombolysis
Βοηθείστε μας να κάνουμε καλύτερο το OpenArchives.gr.
Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών
